spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  sufentanil 

 HSMN NewsFeed - 29 May 2020
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Apr 2020
AcelRx Announces DSUVIA(R) Milestone C Approval and Provides Business Update
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Jun 2018
AcelRx receives European Commission approval for DZUVEO(TM)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 27 Apr 2018
AcelRx receives positive CHMP opinion for DZUVEO(TM) for management of acute moderate to severe pain in medically monitored settings
Biopharmaceutical Drug Delivery Regulatory
 HSMN NewsFeed - 1 Aug 2017
AcelRx Pharmaceuticals Reports Successful Outcome of ZALVISO Phase 3 IAP312 Study on Device Functionality
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 19 Jul 2017
AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2017
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jan 2016
AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 8 Jan 2016
AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso(TM) in 1Q 2016
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Oct 2015
AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2015
AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 2 Jul 2015
Zalviso(TM) Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 26 Sep 2014
AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jan 2014
Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR(R) Pain Patch
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 16 Dec 2013
AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO(TM)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 22 Oct 2013
Pfizer Proceeding with REMOXY(R) Development
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 27 Sep 2013
DURECT Announces Changes to its Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 4 Sep 2013
David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2013
DURECT Announces FDA Acceptance of New Drug Application (NDA) Submission for POSIDUR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 14 Dec 2012
AcelRx to Present Top-Line Data from Phase 3 Study of Sufentanil NanoTab(R) PCA System vs. IV PCA Morphine at the 66th Annual PostGraduate Assembly in Anesthesiology held in New York City
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 4 Jun 2012
AcelRx Pharmaceuticals Completes Private Placement of $10.0 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Apr 2010
AcelRx Pharmaceuticals Names Richard King Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 19 Jan 2010
DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 14 Oct 2009
AcelRx Pharmaceuticals Hires Nigel Ray as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Feb 2009
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2008
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 22 Sep 2008
Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain Patch
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 7 Apr 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2008
Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
Biopharmaceuticals Drug Delivery
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
sufentanil
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.